Psilocybin for OCD: The Evidence, the Mechanism, and the Open Questions

About This Video

Obsessive-compulsive disorder (OCD) is one of the most treatment-resistant psychiatric conditions — first-line pharmacological treatment (SSRIs) benefits only 40-60% of patients, and even treatment responders often retain significant residual symptoms. Psilocybin's serotonin 2A agonism puts OCD among the most mechanistically compelling targets for psychedelic research, and Yale's Dr. Christopher Pittenger — one of the world's leading OCD researchers — presents the evidence and open questions in this departmental grand rounds talk.

The mechanism hypothesis: OCD involves hyperactive cortico-striato-thalamo-cortical loops — repetitive, stuck patterns of neural firing that manifest as intrusive thoughts and compulsive behaviors. Psilocybin's disruption of these rigid neural hierarchies is specifically predicted by the REBUS model to be therapeutic: relaxing the predictive confidence of the loops that maintain OCD symptoms. The 5-HT2A receptor is highly expressed in the prefrontal cortex nodes of these circuits.

The clinical evidence reviewed: a 2006 University of Arizona open-label pilot study (n=9) was the first controlled OCD psilocybin data — and the results were striking. All nine participants showed meaningful OCD symptom reductions lasting hours to days after a single psilocybin dose, with three participants showing complete symptom remission for the duration of observation. Effect sizes were dramatically larger than any existing OCD pharmacotherapy. Yale's Phase 2 trial (launched 2024, n=30) is now generating the first placebo-controlled data for this indication.